NORYVA
IGF-1 LR3
The variant designed to last in cell culture.
1 mg
IGF-1 LR3 is a modified version of IGF-1: the modification reduces its capture by transport proteins, so it stays available longer. That is what made it a cell-culture reagent — and that is its only documented use.
- Cell culture — its documented use.
- Stability that lasts the length of a procedure.
- No human data on this variant.
What is being looked at?
- Cell culture
- Cell growth
- Metabolism
The essentials
- Format
- 1 mg
- Storage · Batch number · Manufactured · Expiry · Batch purity
- On the batch certificate
- Evidence level
- Mechanistic
- Use
- For research and laboratory use only.
The question you are asking yourself
Why is it in the range if it is not for me?
Because it genuinely serves in cell culture, and that is its only documented use. The pathway it uses is also studied for its role in the proliferation of tumour cells. We would rather write that plainly than leave it at the foot of a datasheet.
Why this reference?
It lasts longer in culture medium than the molecule it derives from, which makes it a convenient reagent for work on cells. That is the only reason it appears here, and the only documented use. The pathway it uses is studied, among other things, for its role in the proliferation of tumour cells: this is not a comfort molecule.
What you should know
Scientific detail
What it is
IGF-1 LR3 is a modified analogue of insulin-like growth factor 1. The modification reduces its binding to carrier proteins, which prolongs how long it remains in free form.
Why it is studied
IGF-1 is a central mediator of cell growth. The LR3 analogue was designed as a laboratory reagent, notably for cell culture, where its stability is a practical advantage.
Described mechanism
Activation of the IGF-1 receptor, with the signalling pathways associated with cell proliferation and growth.
What the research has studied
- Cell culture
- Cell growth
- Metabolism
Human data
No human therapeutic data on the LR3 analogue. Not to be confused with recombinant IGF-1, which holds an authorisation in a rare and strictly defined indication: it is neither the same molecule nor the same framework.
Preclinical data
Documented use as a laboratory reagent.
What the data does not say
Stimulating cell growth is not a neutral effect. IGF-1 pathways are studied, among other things, for their role in tumour proliferation; that is a serious reason not to treat this molecule as a lifestyle product. No human safety assessment exists for this analogue.
Regulatory status
For laboratory research purposes only. Not for human consumption or therapeutic use.
This reference holds no marketing authorisation as a medicinal product.
Customer reviews
Frequently asked questions
Can I order IGF-1 LR3 today?
No. This reference is not offered for sale: its commercial framework is not settled. No purchase button is shown until it is.
Does IGF-1 LR3 hold a marketing authorisation?
No. This reference holds no marketing authorisation as a medicinal product and is approved by no authority for human use. A publication or a clinical trial never amounts to approval.
What analyses are available?
The certificate of analysis is supplied with the batch delivered. No batch number or purity figure is published until the real certificate has been entered: we do not display illustrative values.
How is this reference stored?
The storage requirement is not yet on file: the supplier data sheet has not reached us. We would rather say so than assume.
Is it compatible with the NORYVA injector pen?
Compatibility is not confirmed for this reference. Until the manufacturer confirms it, we do not claim it.
What does the available data actually show?
Stimulating cell growth is not a neutral effect. IGF-1 pathways are studied, among other things, for their role in tumour proliferation; that is a serious reason not to treat this molecule as a lifestyle product. No human safety assessment exists for this analogue.
Work out a volume
The vial amount is prefilled from this page. The solvent volume and the amount aimed for are yours to enter: NORYVA proposes neither.